Categories: News

CERNER REPORTS FIRST QUARTER 2022 RESULTS

Margin Expansion Drives Strong Earnings Growth

KANSAS CITY, Mo., May 3, 2022  /PRNewswire/ — Cerner Corporation (Nasdaq: CERN) today announced results for the 2022 first quarter that ended March 31, 2022.

The first quarter earnings release can be viewed here as well as on the company’s website at https://investors.cerner.com/financial-releases.

About Cerner

Cerner‘s health technologies connect people and information systems at thousands of contracted provider facilities worldwide dedicated to creating smarter and better care for individuals and communities. Recognized globally for innovation, Cerner assists clinicians in making care decisions and assists organizations in managing the health of their populations. The company also offers a connected clinical and financial ecosystem to help manage day-to-day revenue functions, as well as a wide range of services to support clinical, financial and operational needs, focused on people. For more information, visit Cerner.com, Cerner Perspectives, connect on Facebook, Instagram, LinkedIn, Twitter or join the discussion on Cerner’s podcast Perspectives on Health & Tech. Nasdaq: CERN.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cerner-reports-first-quarter-2022-results-301538472.html

SOURCE Cerner Corp.

Staff

Recent Posts

Mixie Technologies, Inc. (PHCG) Announces CES Picks Award Recognition for HoloTwin LLC

Recognition by TechRadar Pro at CES 2026 underscores the strategic rationale behind Mixie’s strategic investment…

5 seconds ago

HealthEquity Announces Fiscal Year 2027 Outlook Presentation at J.P. Morgan Healthcare Conference

DRAPER, Utah, Jan. 12, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the…

10 seconds ago

Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer

Experienced medical executive advances to permanent role following successful leadership as Interim CMOSEATTLE and VANCOUVER,…

20 seconds ago

ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM

HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at…

29 seconds ago

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

 -2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY® launch…

49 seconds ago